Information  X 
Enter a valid email address

Clinigen Group plc (CLIN)

  Print      Mail a friend

Tuesday 09 October, 2018

Clinigen Group plc

Clinigen Completes Acquisition of iQone Healthcare

RNS Number : 4167D
Clinigen Group plc
09 October 2018

9 October 2018


Clinigen Group plc


Clinigen Group Completes Acquisition of iQone Healthcare


Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Company'), the global pharmaceutical and services company, announces that it has today completed the acquisition of iQone Healthcare Holding ('iQone'), which was announced on 27 September 2018 (the "Acquisition").

Following the admission to AIM earlier today of the 241,744 new ordinary shares of 0.1p each, issued by Clinigen to satisfy part of the initial consideration for the Acquisition, the Company now has in issue 132,191,498 ordinary shares of 0.1p each, with voting rights. Clinigen does not hold any shares in treasury. This figure of 132,191,498 ordinary shares may be used by shareholders in Clinigen to determine if they are required to notify their interest in, or a change in their interest in, Clinigen under the Financial Conduct Authority's Disclosure and Transparency Rules.


For further information, please contact:

Clinigen Group plc

Tel:+44 (0) 1283 495 010

Shaun Chilton, Group Chief Executive

Martin Abell, Group Chief Financial Officer

Matt Parrish, Head of Investor Relations




Numis Securities Limited

Tel: +44 (0)20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Tom Ballard (Corporate Broking)



RBC Capital Markets  - Joint Broker

Tel: +44 (0)20 7653 4000

Marcus Jackson / Elliot Thomas




Instinctif Partners

Tel:  +44 (0)20 7457 2020

Adrian Duffield / Melanie Toyne-Sewell / Alex Shaw



About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.


For more information, please visit  


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t